Gao A C, Lou W, Dong J T, Isaacs J T
James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
Cancer Res. 1997 Mar 1;57(5):846-9.
We have used microcell fusion-mediated chromosomal transfer to introduce normal human chromosomes into highly metastatic rodent prostatic cancer cells to map the location of a metastasis suppressor gene(s). Using this approach, several chromosomal regions have been identified that harbor such metastatic suppressor genes, including human chromosome 11 between p11.2-13 (T. Ichikawa et al., Cancer Res., 52: 3486-3490, 1992, 54: 2299-2302, 1994; N. Nihei et al., Genes Chromosomes & Cancer, 14: 112-119, 1995; C. W. Rinker-Schaeffer et al., Cancer Res., 54: 6249-6256, 1994). Using positional cloning, a metastatic suppressor gene, termed KAI1, was identified, which is located at human chromosome 11p11.2 (5). Overexpression of KAI1 results in metastasis suppression in certain highly metastatic Dunning R-3327 rat prostatic cancer sublines, such as AT6.1, without metastasis suppression in other highly metastatic sublines, such as AT3.1. This suggests that an additional metastasis suppressor gene is located within the human chromosome 11p11.2-13 region. The CD44 gene is located on human chromosome 11p13 and encodes an integral membrane glycoprotein that participates in specific cell-cell and cell-extracellular matrix interactions. Down-regulation of CD44 expression both at the mRNA and protein levels correlates with metastatic potential within the Dunning system of rat prostatic cancer sublines. Transfection-induced enhanced expression of the Mr 85,000 standard form of CD44 in the highly metastatic AT3.1 rat prostatic cells greatly suppresses their metastatic ability to the lungs without suppression of their in vivo growth rate or tumorigenicity. These results suggest that CD44 is a metastasis suppressor for prostatic cancer and that decreased expression of the standard form of CD44 is involved in the progression of prostatic cancer to a metastatic state.
我们利用微细胞融合介导的染色体转移技术,将正常人类染色体导入具有高度转移性的啮齿类前列腺癌细胞中,以定位转移抑制基因的位置。通过这种方法,已鉴定出几个含有此类转移抑制基因的染色体区域,包括位于p11.2 - 13之间的人类11号染色体(T. Ichikawa等人,《癌症研究》,52: 3486 - 3490,1992;54: 2299 - 2302,1994;N. Nihei等人,《基因、染色体与癌症》,14: 112 - 119,1995;C. W. Rinker - Schaeffer等人,《癌症研究》,54: 6249 - 6256,1994)。通过位置克隆,鉴定出一个名为KAI1的转移抑制基因,它位于人类11号染色体p11.2处(5)。KAI1的过表达在某些高度转移性的Dunning R - 3327大鼠前列腺癌亚系(如AT6.1)中导致转移抑制,但在其他高度转移性亚系(如AT3.1)中则没有转移抑制作用。这表明在人类11号染色体p11.2 - 13区域内还存在另一个转移抑制基因。CD44基因位于人类11号染色体p13上,编码一种参与特定细胞 - 细胞和细胞 - 细胞外基质相互作用的整合膜糖蛋白。在大鼠前列腺癌亚系的Dunning系统中,CD44表达在mRNA和蛋白质水平的下调均与转移潜能相关。在高度转移性的AT3.1大鼠前列腺细胞中,转染诱导的Mr 85,000标准形式的CD44表达增强,极大地抑制了它们向肺部的转移能力,而不抑制其体内生长速率或致瘤性。这些结果表明,CD44是前列腺癌的转移抑制因子,并且CD44标准形式的表达降低与前列腺癌向转移状态的进展有关。